• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

GSK pays $50M for 2 solid tumor cell therapies from Immatics

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Feb 20, 2020 at 10:42: AM
via GlaxoSmithKline has struck a deal to access two Immatics T-cell receptor (TCR) therapeutics. The deal will see GSK pay $50 million (€46 million) upfront and commit to $550 million in milestones for TCRs against two solid tumor targets identified by Immatics.

article source
 




Top Bottom
Back
Quote